Supercharged immune cells aim to stop cancer return after transplant
NCT ID NCT06138587
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This early-phase trial tests whether specially trained natural killer (NK) cells, called CIML NK cells, given with interleukin-2 can safely prevent relapse in people with high-risk acute myeloid leukemia, myelodysplastic syndrome, or related blood cancers after a stem cell transplant. About 15 adults who have measurable disease before transplant will receive the cells by infusion. The main goal is to find a safe dose and check for serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cytokine-induced memory-like natural killer (CIML NK) cells and interleukin-2 (IL-2)
What this could lead to
If it works, this could help prevent leukemia or MDS from coming back after a stem cell transplant, improving long-term survival.
What could go wrong
This is a very early phase 1 trial with only 15 people, focused on safety and dosing. It may not work, and there are risks of side effects like graft-versus-host disease or organ damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.